LYPLAL1 Inhibitors
Chemical inhibitors of LYPLAL1 offer a diverse range of mechanisms to impede its function in various cellular processes. Trifluoperazine, a dopamine receptor antagonist, inhibits LYPLAL1 by modulating G-protein coupled receptor pathways, crucial for LYPLAL1's role in adipogenesis. Similarly, GW 5074 and PD 98059, which target the Raf-1 kinase and MEK in the MAPK/ERK pathway respectively, disrupt cell signaling processes involving LYPLAL1. This leads to an inhibition of LYPLAL1's participation in cell proliferation and differentiation. LY 294002 and Wortmannin, both inhibitors of phosphoinositide 3-kinases (PI3K), exert their inhibitory effects on LYPLAL1 by disrupting the PI3K/Akt pathway. This pathway's disruption hinders LYPLAL1's involvement in critical cellular functions such as cell growth and survival. Rapamycin, targeting the mTOR pathway, also impacts LYPLAL1 indirectly by inhibiting downstream signaling pathways connected to autophagy and metabolism.
Additionally, SB 203580 and SP600125, which inhibit p38 MAPK and c-Jun N-terminal kinase (JNK) respectively, affect LYPLAL1 by altering stress response pathways and cytokine production. U0126, another MEK1/2 inhibitor, further demonstrates how interference with the MAPK/ERK pathway can indirectly inhibit LYPLAL1's signaling roles. Bisindolylmaleimide I targets protein kinase C (PKC), a key player in LYPLAL1-related pathways, thus affecting cell proliferation and differentiation processes where LYPLAL1 is involved. Staurosporine, a broad-spectrum protein kinase inhibitor, and PP 2, a selective inhibitor of Src family kinases, both contribute to the inhibition of LYPLAL1. They act by disrupting various kinase-driven signaling pathways, ultimately affecting LYPLAL1's roles in processes like cell migration and adhesion. Each of these chemicals, through their specific target interactions, converge to inhibit LYPLAL1's functional activities across different cellular contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW 5074 is a potent inhibitor of Raf-1 kinase, a key component of the MAPK/ERK pathway. LYPLAL1 is involved in cell signaling processes that are influenced by the MAPK/ERK pathway. By inhibiting Raf-1, GW 5074 disrupts this pathway, thereby inhibiting the downstream effects mediated by LYPLAL1 in cell signaling and proliferation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which is part of the MAPK/ERK pathway. LYPLAL1, being involved in cell signaling, is affected by changes in the MAPK/ERK pathway. Inhibiting MEK with PD 98059 disrupts the pathway's normal function, leading to the inhibition of LYPLAL1's associated signaling activities. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a specific inhibitor of PI3K, a key player in the PI3K/Akt signaling pathway. LYPLAL1, involved in processes regulated by the PI3K/Akt pathway, is indirectly inhibited by LY 294002. This inhibitor blocks PI3K activity, thereby disrupting the pathway and hindering LYPLAL1's role in associated cellular functions like proliferation and survival. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). Given LYPLAL1's involvement in cellular processes governed by the PI3K/Akt pathway, inhibiting PI3K with Wortmannin indirectly leads to the inhibition of LYPLAL1's functions in these pathways, particularly affecting its role in cell growth and survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor and plays a role in the PI3K/Akt/mTOR pathway. LYPLAL1, involved in signaling pathways that intersect with mTOR signaling, is indirectly inhibited by Rapamycin. This inhibition of mTOR disrupts downstream signaling pathways, affecting LYPLAL1's functional roles in processes like autophagy and metabolism. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway intersects with cellular processes involving LYPLAL1. By inhibiting p38 MAPK, SB 203580 disrupts these signaling pathways, leading to the inhibition of LYPLAL1's functions in cellular stress responses and cytokine production. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), part of the MAPK signaling pathway. LYPLAL1's involvement in cellular signaling processes is influenced by the JNK pathway. Inhibiting JNK with SP600125 disrupts this pathway, thus indirectly inhibiting LYPLAL1's role in cellular responses to stress and cytokines. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a potent inhibitor of MEK1/2, key components of the MAPK/ERK pathway. This inhibition affects LYPLAL1's role in cell signaling, as LYPLAL1 is involved in pathways that are modulated by the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 indirectly inhibits the functional activities of LYPLAL1 in these pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). PKC plays a role in signaling pathways that intersect with LYPLAL1's functions. Inhibiting PKC with Bisindolylmaleimide I disrupts these signaling pathways, thereby inhibiting LYPLAL1's roles in processes such as cell proliferation and differentiation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of a broad spectrum of protein kinases. While it affects various kinases, its inhibition of specific kinases involved in pathways where LYPLAL1 is active indirectly leads to the inhibition of LYPLAL1's functional roles in cell signaling and regulation. | ||||||